Repligen’s first quarter results were met positively by the market, reflecting solid execution across core product lines and robust demand in both analytics and consumables. Management attributed the performance to broad-based growth, with analytics leading segment gains and Asia Pacific—particularly China—showing substantial momentum. CEO Olivier Loeillot highlighted the resurgence in capital equipment demand and improving order trends, stating, “Analytics led the way with 50% plus growth, but all of our franchises grew nicely again in the first quarter.” The divestiture of the low-margin Polymem business and continued cost discipline contributed to margin improvements, setting a constructive tone for near-term profitability.
Is now the time to buy RGEN? Find out in our full research report (it’s free for active Edge members).
Repligen (RGEN) Q1 CY2026 Highlights:
- Revenue: $194.3 million vs analyst estimates of $191.7 million (14.8% year-on-year growth, 1.3% beat)
- Adjusted EPS: $0.48 vs analyst estimates of $0.38 (24.9% beat)
- Adjusted EBITDA: $40.01 million vs analyst estimates of $33.73 million (20.6% margin, 18.6% beat)
- The company dropped its revenue guidance for the full year to $818 million at the midpoint from $825 million, a 0.8% decrease
- Management raised its full-year Adjusted EPS guidance to $2.01 at the midpoint, a 2% increase
- Operating Margin: 8.2%, up from 3.9% in the same quarter last year
- Organic Revenue rose 11% year on year (beat)
- Market Capitalization: $6.54 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Repligen’s Q1 Earnings Call
- Dan Arias (Stifel) asked how much of margin expansion was due to mix versus structural changes. CFO Jason Garland clarified that the first quarter benefited from both favorable product mix and volume leverage, with structural improvements expected to build over time through the transformation office.
- Madeline Mollman (Wolf Research) inquired about capital equipment order momentum and RFP wins. CEO Olivier Loeillot explained that March saw accelerated orders, particularly in China, and positive responses to recent RFPs, though customer decision cycles remain gradual.
- Matthew Larew (William Blair) questioned the sustainability of emerging biotech recovery. Loeillot said growth is encouraging but spending remains below historical levels, emphasizing that a full sector rebound will depend on further disbursement of biotech funding.
- Philip Song (Leerink Partners) probed the China revenue surge and OEM partnership impact. Loeillot noted that the OEM deal has yet to contribute directly but is enhancing Repligen’s profile for local customers and should support future growth.
- Brendan Smith (TD Cowen) asked for detail on the transformation office’s margin optimization focus. Loeillot stated that efforts target manufacturing, product rationalization, customer service, and IT/AI implementation, aiming to close margin gaps across product lines.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be monitoring (1) the pace of analytics product adoption and the sustainability of double-digit growth across high-margin segments, (2) the operational impact and tangible benefits from transformation office initiatives, and (3) the trajectory of emerging biotech and China market demand. Additional focus will be placed on the rollout of local partnerships in Asia and the effect of biotech funding trends on equipment and consumable sales.
Repligen currently trades at $118.50, in line with $118.21 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
